[go: up one dir, main page]

ES2544153B1 - Uso de un hidrolizado de caseína como agente antiviral - Google Patents

Uso de un hidrolizado de caseína como agente antiviral Download PDF

Info

Publication number
ES2544153B1
ES2544153B1 ES201430248A ES201430248A ES2544153B1 ES 2544153 B1 ES2544153 B1 ES 2544153B1 ES 201430248 A ES201430248 A ES 201430248A ES 201430248 A ES201430248 A ES 201430248A ES 2544153 B1 ES2544153 B1 ES 2544153B1
Authority
ES
Spain
Prior art keywords
casein hydrolyzate
antiviral agent
prevention
present
opportunistic virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201430248A
Other languages
English (en)
Other versions
ES2544153A1 (es
Inventor
Pere ADELL WINKLER
Guillermo LÓPEZ ZARCO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTD Labs SL
Original Assignee
NTD Labs SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201430248A priority Critical patent/ES2544153B1/es
Application filed by NTD Labs SL filed Critical NTD Labs SL
Priority to US15/121,080 priority patent/US10772927B2/en
Priority to DK15710916.6T priority patent/DK3110430T3/da
Priority to ES15710916T priority patent/ES2746523T3/es
Priority to EP15710916.6A priority patent/EP3110430B1/en
Priority to PT157109166T priority patent/PT3110430T/pt
Priority to PCT/IB2015/051157 priority patent/WO2015125067A1/en
Publication of ES2544153A1 publication Critical patent/ES2544153A1/es
Application granted granted Critical
Publication of ES2544153B1 publication Critical patent/ES2544153B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de un hidrolizado de caseína como agente antiviral.#La presente invención se refiere al uso de un hidrolizado de caseína como agente antiviral para el tratamiento de infecciones por virus oportunistas, especialmente por herpesvirus y el virus del papiloma humano. Dicho hidrolizado de caseína tiene aplicación tanto en el tratamiento terapéutico de los síntomas establecidos como en la prevención de la infección o de la reactivación de una infección latente por un virus oportunista. El hidrolizado de caseína de la presente invención es efectivo para la prevención de las infecciones por virus oportunistas en individuos con el sistema inmunitario debilitado.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22

Claims (1)

  1. imagen1
    imagen2
ES201430248A 2014-02-24 2014-02-24 Uso de un hidrolizado de caseína como agente antiviral Expired - Fee Related ES2544153B1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES201430248A ES2544153B1 (es) 2014-02-24 2014-02-24 Uso de un hidrolizado de caseína como agente antiviral
DK15710916.6T DK3110430T3 (da) 2014-02-24 2015-02-17 Brug af kasein hydrolysat som en antiviral agent
ES15710916T ES2746523T3 (es) 2014-02-24 2015-02-17 Uso de un hidrolizado de caseína como agente antivírico
EP15710916.6A EP3110430B1 (en) 2014-02-24 2015-02-17 Use of a casein hydrolysate as an antiviral agent
US15/121,080 US10772927B2 (en) 2014-02-24 2015-02-17 Use of a casein hydrolysate as an antiviral agent
PT157109166T PT3110430T (pt) 2014-02-24 2015-02-17 Utilização de um hidrolisado de caseína como um agente antiviral
PCT/IB2015/051157 WO2015125067A1 (en) 2014-02-24 2015-02-17 Use of a casein hydrolysate as an antiviral agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430248A ES2544153B1 (es) 2014-02-24 2014-02-24 Uso de un hidrolizado de caseína como agente antiviral

Publications (2)

Publication Number Publication Date
ES2544153A1 ES2544153A1 (es) 2015-08-27
ES2544153B1 true ES2544153B1 (es) 2016-06-06

Family

ID=52693000

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201430248A Expired - Fee Related ES2544153B1 (es) 2014-02-24 2014-02-24 Uso de un hidrolizado de caseína como agente antiviral
ES15710916T Active ES2746523T3 (es) 2014-02-24 2015-02-17 Uso de un hidrolizado de caseína como agente antivírico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15710916T Active ES2746523T3 (es) 2014-02-24 2015-02-17 Uso de un hidrolizado de caseína como agente antivírico

Country Status (6)

Country Link
US (1) US10772927B2 (es)
EP (1) EP3110430B1 (es)
DK (1) DK3110430T3 (es)
ES (2) ES2544153B1 (es)
PT (1) PT3110430T (es)
WO (1) WO2015125067A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073824B1 (ko) * 2018-04-11 2020-02-05 강원대학교산학협력단 간 보호용 건강기능식품 및 이의 제조 방법
FR3083981B1 (fr) * 2018-07-20 2021-01-15 Semiocare Sas Compositions a usage cosmetique et dermatologique
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
ES2940736B2 (es) * 2021-11-09 2023-09-19 Ntd Labs S L U Uso combinado de imiquimod y de un hidrolizado de caseina para el tratamiento de condilomas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922453A1 (de) 1989-07-07 1991-01-17 Gauri Kailash Kumar Pharmakologisch wirksame produkte aus molkeproteinhydrolysaten und verfahren zu deren gewinnung
WO1992017191A1 (en) 1991-04-01 1992-10-15 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
CA2285572A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. A method for treating papillomavirus infections
WO2000001720A2 (en) 1998-07-02 2000-01-13 President And Fellows Of Harvard College Compositions and methods for treating papillomavirus-infected cells
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
NZ526271A (en) * 2000-12-07 2005-02-25 Dsm Ip Assets B Protein hydrolysates enriched in peptides having a carboxy terminal proline residue
TWI317636B (en) * 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
AU2003277644A1 (en) * 2002-11-29 2004-06-23 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
NZ545341A (en) * 2003-08-01 2009-06-26 Calpis Co Ltd Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food
WO2011138489A1 (es) * 2010-05-06 2011-11-10 Consejo Superior De Investigaciones Científicas (Csic) Uso de hidrolizados de caseínas como antivirales
CN104703601A (zh) 2012-07-03 2015-06-10 格雷斯兰生物科技股份有限公司 用于治疗和抑制病毒感染的组合物和方法
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético

Also Published As

Publication number Publication date
EP3110430B1 (en) 2019-06-26
US10772927B2 (en) 2020-09-15
US20160361374A1 (en) 2016-12-15
WO2015125067A1 (en) 2015-08-27
ES2544153A1 (es) 2015-08-27
EP3110430A1 (en) 2017-01-04
PT3110430T (pt) 2019-10-15
DK3110430T3 (da) 2019-09-23
ES2746523T3 (es) 2020-03-06

Similar Documents

Publication Publication Date Title
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
SV2018005610A (es) Derivados de oxopiridina sustituidos
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
BR112017005104A2 (pt) derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina
CL2015003298A1 (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
CL2016000381A1 (es) Compuestos antivirales
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
HUE037347T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
ES2544153B1 (es) Uso de un hidrolizado de caseína como agente antiviral
MX2021014844A (es) Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.
MX363464B (es) Vacunas contra influenza h5.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
DOP2017000115A (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
UY36540A (es) Anticuerpos monoclonales humanos dotados de fuerte actividad neutralizadora contra los virus herpes simple tipo 1 (hsv-1) y tipo 2 (hsv-2)
UY39206A (es) Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: NTD LABS, S.L.

Effective date: 20150522

FG2A Definitive protection

Ref document number: 2544153

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160606

FD2A Announcement of lapse in spain

Effective date: 20211004